Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finetuning The Art Of Leveraging Past Notified Body Assessments Of Technical Documentation

Executive Summary

Recent experience gained on submitting technical documentation to notified bodies in a way that can speed up product assessments has led to a revision of guidance issued last October, as well as to work on a new paper to further streamline the notified body work related to this documentation.

You may also be interested in...



TEAM-NB To Roll Out Evidence Of Compliance With Extended MDR Period Rules 'Soon'

Questions about how manufacturers are going to demonstrate their legacy products may remain on the EU market beyond the former 24 May 2024 deadline have abounded. One vital instrument to demonstrate ongoing compliance is soon to be available.

More Flexible Approach Proposed For EU Notified Body Technical Documentation Reviews

Shortfalls in manufacturer technical documentation submitted to notified bodies cause delays for manufacturers and notified bodies alike. A new document from the notified body association, TEAM-NB, aims to streamline processes.

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel